We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Please provide feedback for this on the following(scale 1-5, 1 strongly disagree; 5 strongly agree):
* = Mandatory Field
The Yellow III study aimed to assess the effect of evolocumab in combination with statins on plaque morphology in patients with stable coronary artery disease. In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai Medical Centre, New York, NY, USA) to discuss the Yellow series, with focus on the […]
Evolocumab is a proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9 inhibitor). When used in combination with statins, reduced plaque volume has been observed in patients with acute coronary syndrome (ACS). In this touchCARDIO interview, we speak with Dr Annapoorna Kini (Cardiac Catheterization Laboratory, Mount Sinai Medical Centre, New York, NY, USA) to discuss the use […]
The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient’s clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) to discuss the current guidelines for the […]
The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) highlights the findings from the […]
The REVIVED-BCIS2 trial assessed the use of myocardial viability tests in predicting prognosis following revascularization in patients with ischaemic left ventricular dysfunction. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the REVIVED-BCIS2 trial, its findings and the impact these results will likely […]
Ischaemic left ventricular dysfunction is encountered frequently by physicians. Myocardial viability tests are utilised as a prospective tool that enables prediction of a patient’s recoverability. In this touchCARDIO interview, we speak with Professor Divaka Perera (Guy’s and St Thomas’ NHS Foundation Trust, London, UK) to discuss the treatment paradigm for ischaemic left ventricular dysfunction and […]
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Despite recent advancements in the treatment of pulmonary arterial hypertension (PAH), there are still several treatment gaps and unmet needs that exist. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany) to explore the need for more effective therapies that target multiple pathways involved in […]
Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, […]
Get the latest clinical insights from touchCARDIO